NITD-916 is primarily researched for its potential in combating tuberculosis (TB), particularly drug-resistant strains. It functions as a potent inhibitor of the enzyme DNA gyrase, which is crucial for bacterial DNA replication. By targeting this enzyme, NITD-916 disrupts the bacterial lifecycle, making it a promising candidate for TB treatment. Its application is significant in developing new therapeutic options, especially in regions where multidrug-resistant TB is prevalent. Ongoing studies focus on optimizing its efficacy and safety profile for clinical use.